Biotechnology

Artis BioSolutions is opening a new synthetic DNA facility in Boston, aiming to reduce supply chain risks and accelerate next-gen medicine development.

With new financing from Avenue Capital, Turn Therapeutics bets big on its novel skin therapy, GX-03, to tackle multi-billion dollar dermatology markets.

A US-Japan biotech firm secures major funding to advance a first-in-class drug, offering new hope for millions with inherited blood disorders.

A new alliance between Discovery Life Sciences and Mindpeak aims to solve inconsistent biomarker interpretation, a critical bottleneck in cancer drug development.

Private equity firm Southfield Capital has acquired a majority stake in Metric Search, aiming to dominate the high-stakes recruitment market for niche talent.

The CRDMO giant posted a 16.7% revenue jump in 2025, driven by a massive pipeline expansion and a strategic pivot to next-generation biologics.

Merck's breakthrough PAH drug is now covered in several provinces, offering new hope. But what about its high cost and access for the rest of Canada?

A new platform is launching to connect pharma companies directly with 70+ global regulators, promising to slash approval times and speed patient access.

With positive safety data for its novel UC drug, a €530M cash reserve, and a new commercial chief, Abivax is poised for a major market entry.

A new Phase 2 trial is testing an inhaled version of a key IPF drug, aiming to reduce severe side effects and transform treatment for the fatal lung disease.

With a cash runway into 2027, the biotech firm prepares for critical data on its innovative bispecific antibody pipeline for hard-to-treat solid tumors.

Wilmington PharmaTech is doubling its API capacity, a key move to bolster the U.S. drug supply chain and reduce reliance on foreign manufacturing.

With over AUD$1M in sales from its first MDMA batch, Cortexa is validating Australia's pioneering move to legalize psychedelic-assisted therapy.

The life sciences analytics provider earned a top sustainability rating, signaling a shift where ESG performance is now critical for pharma partnerships.

Tempest Therapeutics raises up to $6M in a critical financing deal to advance its CAR-T pipeline, balancing promising clinical data with financial pressures.

The bioconjugate CRDMO reports record profits and a $1.49B backlog, fueled by tech innovation, strategic acquisitions, and global expansion.

Ephicacy appoints biometrics SVP Jamie Powers and India Head Tyagi Swaminathan in a strategic push to dominate advanced clinical trial analytics.

A key preclinical success in a $570M partnership advances a novel therapy designed to reset the immune system for patients with lupus, MS, and arthritis.

Lifecore Biomedical secures its third major manufacturing deal in five months, signaling a strategic shift that could reshape the aesthetics supply chain.

With key trial enrollment complete, Pyxis Oncology refines its cancer drug MICVO for safety and prepares for pivotal data under a new, seasoned CEO.